Kornimate/medical-research-clean huggingface dataset:
effects of antiviral therapy on hbv reactivation

Conditions: Liver Cancer

Summary: hepatitis b virus (hbv) reactivation happens after liver resection for hbv-related hepatocellular carcinoma (hcc) patients, particularly for those with positive serum hbv-dna . the incidence rate and risk factors of hbv reactivation after hepatectomy for serum hbv-dna negative hbv-related hcc are unclear.

hepatitis b virus (hbv) reactivation happens after liver resection for hbv-related hepatocellular carcinoma (hcc) patients, particularly for those with positive serum hbv-dna . the incidence rate and risk factors of hbv reactivation after hepatectomy for serum hbv-dna negative hbv-related hcc are unclear.from july 2012 to december 2015, 174 consecutive patients with serum hbv-dna negative hbv-related hcc underwent resection were prospectively enrolled in the studied. there are 66 patients received preoperative antiviral therapy (antiviral group) and 108 patients did not receive any antiviral therapy (non-antiviral group). the incidence of hbv reactivation, risk factors of liver function were analyzed in perioperative period. hbv reactivation developed in 30 patients (27.8%) in the non- antiviral group and 2 patients (3.0%) in the antiviral group, respectively (p \< 0.001). multivariate analysis revealed that minor hepatectomy (hr, 4.695; 95% ci, 1.257-17.537, p = 0.021) and without antiviral therapy (hr, 8.164; 95% ci, 1.831-36.397, p =0.006) were risk factors attributed to hbv reactivation. patients in antiviral group and non-antiviral group or reactivation group and without reactivation group have similar alt, tbil, alb, and pt in 7 days after resection. however, patients in antiviral group have significantly better alt and alb on day 30th after resection than those in control group. moreover, similar phenomenon were observed when comparing those with or without hbv reactivation. resection could lead to hbv reactivation during the perioperative period for serum hbv dna negative hbv-related hcc, especially in patients who did not receive any antiviral therapy. anti-hbv therapy can reduce the risk of reactivation, thus improving liver function after hepatectomy.

Eligibility criteria:
inclusion criteria: * underwent initial hepatectomy; * preoperative serum hbsag positive * serum hbv dna negative * serum alt in normal range * child-pugh a liver function * hcc was confirmed by histopathology * patients in the treated group received entecavir (ent) while patients in the control group did not receive any antiviral therapy. exclusion criteria: * underwent preoperative tace or other anti-tumor treatments * underwent preoperative antiviral treatment for nearly a year * with autoimmune disease, other organ malignant tumor, or other severe disease.
persistent post surgical pain after total knee arthroplasty

Conditions: Knee Arthropathy

Summary: patients undergone total knee replacement are randomized to receive a "fast track" regional anesthesia protocol or a "traditional" regional anesthesia continuous infusion by both a femoral and sciatic catheter to assess if this latter technique may reduce persistent postoperative pain six months after surgery

patients undergone to primary total knee replacement with spinal anesthesia are randomized to receive a continuous adductor canal block infusion + an ipack block or a continuous femoral nerve block + a continuous sciatic nerve block just at the end of surgery. both group will receive a multimodal analgesia with paracetamol, ketorolac, desametasone and morphine as a rescue.

Eligibility criteria:
inclusion criteria: * primary total knee replacement with a written informed consent exclusion criteria: * allergy to local anesthetics or any drugs involve in the study * controindication to regional anesthesia * chronic use of opioids * bmi \> 35 kg m2

Keywords: knee arthroplasty acute postoperative pain persistent post surgical pain regional anesthesia
switch of renin-angiotensin system inhibitors in patients with covid-19

Conditions: Covid19; Angiotensin II Receptor Antagonist Adverse Reaction

Summary: the switch-covid trial will randomize patients with covid-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.

patients eligible for the study, after signing informed consent will be randomized 1:1 for maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy for other classes according to a pre-specified protocol. patients are going to be followed during hospital stay for evaluation of clinical endpoints. also blood and urine samples will be acquired for evaluation of renin-angiotensin system activation.

Eligibility criteria:
inclusion criteria: * hypertension in use of renin-angiotensin system inhibitors * confirmed covid-19 infection by rt-pcr, serology tests or typical clinical presentation and chest ct. * symptoms onset \< 96h * need for hospitalization exclusion criteria: * heart failure * previous cerebrovascular disease * previous myocardial infarction * blood pressure \> 180 x 100 mmhg * need for 3 or more anti-hypertensive classes * use os spironolactone * severe pulmonary disease * contraindication for using other anti-hypertensive classes (calcium channel blockers, hydralazine, diuretics or nitrates)

Keywords: covid19 ace inhibitors ace2
evaluation of efficiency in cancerology of new technologies as telemedicine and conected objects (e-domsanté)

Conditions: Breast Cancer

Summary: observational study about patients treated for a metastasis breast cancer who live far from their comprehensive cancer center and followed by telemedicine, connected wtaches and patient-reported symptom monitoring.

every week, each patient report her symptoms and answer ten questions on the i-pad. the connected watch reports the performance status (activtiy and time spent in bed or sitting), and the falls. if nurses or doctors detect any problem, they ask the patient for a telemedicine to try to help her. during the same time, nurses or doctors send a message on a secure plateform to the local team (nurse, general practitioner, and pharmacists) and they reserve a place for an hospitalization if necessary.

Eligibility criteria:
inclusion criteria: * women more than 18 years old * treated for an advanced metastasis breast cancer * who live far from their comprehensive cancer center in the landes department exclusion criteria: * women who are not able to understand the study because of psychiatric disease

Keywords: telemedicine connected watches patient-reported symptom monitoring secure platform
virtual reality mediated functional status assessment in stroke patients

Conditions: Hemiplegia

Summary: the aim of the study is to investigate the applicability of virtual reality-mediated functional status assessment of patients diagnosed with stroke. remote assessment of patients and remote rehabilitation (tele-rehabilitation) has an increasing application area in individuals with chronic neurological diseases. in this study, it was aimed to evaluate the upper extremity and balance functions of stroke patients with the developed software.

this prospective and descriptive study will be conducted with patients diagnosed with stroke. patients diagnosed with stroke will first be evaluated by an expert physiatrist in a clinical setting to determine their functional status, and then evaluated by a virtual reality mediated software system. the evaluation of a patient will take approximately 1 hour. participants diagnosed with stroke will be evaluated in terms of hand and balance functions. the measurement parameters planned to be performed are scales routinely applied in stroke patients. hand functions of the users will be evaluated with the 'wooden box and block test' , lower extremity muscle strength and fall risk will be evaluated with the 'sit and stand test for 5 times', and balance functions will be evaluated with the '360 degree rotation test' . the tests mentioned above will be presented to the users first in the real world and then in the virtual reality environment and an objective functional status assessment will be made. a total of 30 patients diagnosed with stroke are planned to be included in the study.

Eligibility criteria:
inclusion criteria: * to be between the ages of 18-65, * history of stroke * accept to participate in the study, exclusion criteria: * presence of known central nervous system or peripheral nervous system disease other than stroke, presence of progressive neurological deficit, * uncontrolled hypertension, diabetes, cardiovascular disease etc. * cognitive impairment causing difficulty in performing simple commands * epilepsy * pregnancy.

Keywords: virtual reality assessment
artificial intelligence 3d augmented reality robot-assisted-radical- prostatectomy v.s. no3d intervention

Conditions: Cancer of Prostate

Summary: this is a prospective randomized multicenter study aimed at comparing 3d ai-ar-rarp vs. no 3d, verifying the impact of this new technology on oncological and functional outcomes after the procedure.

considering that prostate cancer lesions are not identifiable during surgery, except in the case of extensive and advanced tumors, the surgeon does not have a real-time perception of the location of the tumor. the absence of clear spatial visualization can therefore lead to a positive surgical margin, particularly in tumors in the t3 stage (invasion of the prostatic capsule or seminal vesicles). our hypothesis is that with the help of ai 3d ar during surgery, positive surgical margins can be avoided, or at least reduced, while preserving the neurovascular bundles, with a consequent improvement not only in postoperative functional outcomes (continence and potency), but also oncological ones (less biochemical disease recovery (bcr), less need for salvage radiotherapy, lower risk of metastasis).

Eligibility criteria:
inclusion criteria: 1. signature of the written informed consent and consent to the use of personal data 2. age \> 40 years and male sex 3. pre-operative mri performed according to esur recommendations and reporting in accordance with pirads v.2 4. disease with evidence of bulging or radiological t3 on pre-operative mri 5. histological diagnosis of acinar type prostate cancer in the area highlighted on mri 6. absence of bulky (\>3 cm), bony or visceral retroperitoneal or pelvic lymph node metastatic lesions 7. patients eligible for radical prostatectomy + pelvic lymphadenectomy 8. ecog ps 0-1 9. life expectancy ≥ 5 years 10. patients motivated to preserve erection and with pre-operative sexual activity with iief \>17 11. availability of the patient's pre-operative clinical data 12. patients must be available to carry out the visits foreseen in the follow-up of the protocol and consent to data collection exclusion criteria: 1. special histotypes of prostate cancer 2. patients with psa \> 100 ng/ml at diagnosis 3. inability to perform mri (pacemaker wearers, claustrophobia...) or mri of inadequate quality to obtain the ha3dtm 3d reconstruction 4. concomitant treatment with other antineoplastic drugs including investigational endocrine therapies 5. serious uncontrolled concomitant medical condition or disease including active, uncontrolled infections 6. patients with dementia or psychiatric illness that limit compliance with study requirements or that may prevent understanding and/or signing informed consent.

Keywords: 3d ai-ar-rarp cancer of prostate prostate surgery hyper-accuracy 3d reconstruction (ha3dtm) riders computer vision robot-assisted laparoscopic radical prostatectomy
a comparative study of an integrated pharmaceutical care plan and a routine care in bronchial asthma

Conditions: Bronchial Asthma

Summary: the aim of the study is to compare the effect of asthma care by clinical pharmacist intervention versus routine care on asthma control.


Eligibility criteria:
inclusion criteria: * patient with clinical diagnosis of bronchial asthma * responsible for administering their own asthma medications. exclusion criteria: * patients who were not responsible for administering their own asthma medications. * patients with cognitive defects, other pulmonary disease e.g. chronic obstructive pulmonary disease (copd), experiencing illness with asthma-like symptoms e.g. congestive heart failure, evidence of fixed airway obstruction * patients unavailable for 2-month follow-up. * patients who did not provide written informed consent.
dipraglurant (adx48621) for the treatment of patients with parkinson's disease receiving levodopa-based therapy

Conditions: Parkinson Disease; Dyskinesia, Drug-Induced; Dyskinesias

Summary: this study is designed to evaluate the safety and efficacy of dipraglurant in pd patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). the primary efficacy assessment will be based on the unified dyskinesia rating scale (udysrs). patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.


Eligibility criteria:
inclusion criteria: * patients with parkinson's disease on a stable regimen of antiparkinson's medications, including a levodopa preparation administered not less than 3 times daily. * meet protocol-specified criteria for moderate to severe dyskinesia symptoms based on udysrs and movement disorder society - unified parkinson's disease rating scale (mds-updrs) assessments. * meet protocol specified criteria for on time with troublesome dyskinesia based on a standard pd home diary. exclusion criteria: * prior surgical treatment for parkinson's disease (e.g., deep brain stimulation). * other neurological disease (including psychiatric disease and/or cognitive impairment) that, in the opinion of the investigator, would affect the patient's ability to complete study assessments. * other significant medical condition that may affect the safety of the patient or preclude adequate participation in the study. * pregnant or breast-feeding. female patients who are of child-bearing potential must be using adequate contraceptive methods (e.g. oral contraceptive, double-barrier method, intra-uterine device, intra-muscular hormonal contraceptive), and have a negative pregnancy test at screening. other protocol-defined inclusion and exclusion criteria may apply

Keywords: parkinson's disease dyskinesia levodopa-induced dyskinesia
malignancy meta analysis for brl49653

Conditions: Diabetes Mellitus, Type 2

Summary: observational analyses of data from population registeries have suggested that metformin may be associated with a decreased prevalence of malignancy. the adopt and record studies both contain groups of subjects randomly allocated to metformin and rosiglitazone. this meta-analysis combines malignancy serious adverse events from adopt and record in order to compare their incidence on metformin with that on rosiglitazone.

the objective of this meta-analysis is to compare the incidence of malignancy (excluding non-melanomatous skin cancers) reported as serious adverse events in the adopt and record studies between subjects randomly allocated to treatment with metformin with those allocated to rosiglitazone.

Eligibility criteria:
subjects from adopt that are included in this meta-analysis (those in the metformin or rosiglitazone groups) had the dose of their study medication increased to a maximum of 2g (metformin) or 8mg (rosiglitazone) if their fasting plasma glucose was greater than 140mg/dl. subjects from record that are included in this meta-analsyis entered the record study taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride). they were randomly allocated to metformin or rosiglitazone in a 1:1 ration to use as add-on treatment to the background of sulfonylurea. these subjects had the dose of their study medication increased to a maximum of 2.55g (metformin) or 8mg (rosiglitazone) if their hba1c was greater than 7.0%.

Keywords: rosiglitazone adopt metformin malignancy record
comparison of conservative methods for the treatment of lateral epicondylitis: a randomized, prospective study

Conditions: Tennis Elbow; Lateral Epicondylitis

Summary: this is a prospective study where patients with lateral epicondylitis (tennis elbow) will be randomized into one of 4 possible treatments. the purpose is to individually examine the efficacy of each treatment, and determine if one treatment method is more effective than another. the four treatments are: corticosteriod injections, prolotherapy, nsaids (non-steroidal anti-inflammatory drugs) combined with physical therapy, and a placebo.


Eligibility criteria:
inclusion criteria: * pain over the lateral epicondyle (via palpation over the lateral epicondyle, resisted wrist extension, resisted finger extension of the middle finger) for less than six-months duration prior to enrollment * conservative treatment of tennis elbow is recommended as standard of care treatment * over the age of 18 and under the age of 65 * ability to give informed consent exclusion criteria: * treatment by a health care profession (md, physicians assistnat, therapist, or nurse practitioner) within the previous 6 months for tennis elbow * congenital deformities, tendon ruptures, or fractures of the elbow within the previous 12 months * immobility casts or splints within the last 6 months for tennis elbow * co-existing elbow diagnosis (i.e. osteoarthritis or instability) * pregnant women, women trying to get pregnant, or breastfeeding women * under the age of 18 or over the age of 65

Keywords: tennis elbow lateral epicondylitis
zambia infant cohort study - brains optimized for surviving and thriving

Conditions: Child Development

Summary: children exposed to hiv in-utero but uninfected (cheus) number 14.8 million globally. in zambia, an estimated 56,000 cheus are born annually, a staggering fraction of the national birth cohort. multiple studies establish that cheus are more neurodevelopmentally vulnerable than hiv-unexposed peers. in zambia, there are existing effective early childhood developmental (ecd) interventions that target other vulnerable populations, but never trialed specifically for cheus. scaling up ecd is now a priority of zambia's national strategy, but cheus are not currently targeted. there is a need to better understand the scope and mechanism of cheu-related neurodevelopmental differences and what interventions are most effective. this randomized clinical trial (rct) is a true effectiveness trial as the intervention will deploy a home-based adaptation of the same curriculum that is currently used elsewhere in the country, named scaling up early childhood development in zambia (supercdz). the effectiveness of a scalable early childhood development (ecd) intervention for cheus will be evaluated using normalized z-scores of neurodevelopmental testing at age 24 months. in this rct the investigators will test the following hypotheses: hypothesis 1: an ecd intervention delivered by community health workers via bi-weekly home visits will improve neurodevelopmental outcomes in cheus. hypothesis 2: cheus have significantly worse neurodevelopmental outcomes than unexposed peers at 24 months, mediated by preterm birth, disease stage or antiretroviral (arv) exposure. this rct will build on an existent, actively recruiting cohort of 1500 pregnant women-infant dyads in a peri-urban hospital in zambia, the zambian infant cohort study (zics), by extending the follow-up of a subsample of infants from 6 months to 2 years amongst the last 525 children enrolled (zics-boost- brains optimized to survive and thrive). the study will have three arms: arm 1) cheu + ecd intervention (n=175); arm 2) cheu without ecd intervention (n=175); arm 3) huu without intervention (n=175).


Eligibility criteria:
inclusion criteria: * zambia infant cohort study (zics) cohort participants who are \>18 years old and are still pregnant or whose infants are less than 9 months of age by february 2022. * zics inclusion criteria were pregnant women (1:1, hiv+:hiv-) presenting for antenatal care at chawama first level hospital and intending to deliver at chawama first level hospital and less than 26 weeks gestation by ultrasound exclusion criteria: * mother-infant dyads not enrolled in zics * mother-infant dyads where mother is \<18 years of age

Keywords: children exposed to hiv in-utero but uninfected (cheus) early childhood developmental (ecd) interventions community health workers home visits zambia
perfusion index and labor analgesia

Conditions: perfüsion Index in Removal of the Epidural Analgesia

Summary: it can be suggested that sympathetic tonus increase and pain, caused by the removal of the effect of epidural analgesia applied at birth, may also affect perfüsion index. the purpose of this study is; to correlate the vas value at the time of return of epidural analgesia with the pi values at that time and, to test the possibility of using pi variants as an objective tool for predicting pain initiation time and assessing pain.


Eligibility criteria:
inclusion criteria: * women who will give normal spontaneous vaginal delivery * between the ages of 18-45 exclusion criteria: * patients who do not accept the procedure, * those under 18 years of age - over 45 years, * those with low platelet counts, * those with infection at the puncture site, * those with progressive neurological disease, * those with increased intracranial pressure, * those with hypovolemia

Keywords: perfüsion index epidural analgesia labor
methylation analysis of circulating tumor dna in gastric cancer

Conditions: Stomach Neoplasms; Circulating Tumor DNA

Summary: the primary purpose of this trial is to describe the profile of ctdna methylation in gastric cancer. the second purpose is to demonstrate the correlation between the plasma ctdna methylation status and the diagnosis and prognosis of patients with early and intermediate stage gastric cancer.

gastric cancer represents one of the common malignant tumors in china, with high incidence and mortality rates. surgery is the conventional treatment option for early and intermediate stage gastric cancer, but the diagnosis in the early stage of gastric cancer remains a challenge to clinical practitioners. circulating tumor dna (ctdna) is tumor-derived fragmented dna with an average size of 166 bp, mixed with cell-free dna (cfdna) of other sources in blood circulation. ctdna is reflecting the most up-to-date status of the tumor genome. hence, it is considered as a novel biomarker for tumors, which can be qualitative, quantitative, and used for disease monitoring. this study is designed to evaluate the potential clinical utility of circulating tumor dna (ctdna) as a clinical index in the diagnosis and prognosis of gastric cancer. the primary purpose of this trial is to describe the profile of ctdna methylation in gastric cancer. the second purpose is to demonstrate the correlation between the plasma ctdna methylation status and the diagnosis and prognosis of patients with early and intermediate stage gastric cancer.

Eligibility criteria:
inclusion criteria: 1. the subject is scheduled to undergo an endoscopy because of medical indications. 2. the subject must have personally signed and dated the patient informed consent form indicating that he/she has been informed of all pertinent aspects of the study. 3. the subject must be willing and able to comply with all study procedures. exclusion criteria: 1. the subject who is unable to undergo gastroscopy. 2. the subject with previous total or partial gastrectomy. 3. the subject has other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and in the judgment of the investigator would make the subject unsuitable for entry into the study. 4. the subject is unwilling or unable to provide signed informed consent. 5. the subject who is pregnant.